EFFECT OF LITHIUM IN IMMUNODEFICIENCY - IMPROVED BLOOD-CELL FORMATION IN MICE WITH DECREASED HEMATOPOIESIS AS THE RESULT OF LP-BM5 MULV INFECTION

被引:24
作者
GALLICCHIO, VS
HUGHES, NK
TSE, KF
LING, J
BIRCH, NJ
机构
[1] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT INTERNAL MED,LEXINGTON,KY 40536
[2] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536
[3] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT CLIN SCI,LEXINGTON,KY 40536
[4] UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT TOXICOL,LEXINGTON,KY 40536
[5] VET ADM MED CTR,DEPT VET AFFAIRS,LEXINGTON,KY 40536
[6] UNIV WOLVERHAMPTON,SCH HLTH SCI,BIOMED RES LAB,WOLVERHAMPTON WV1 1DJ,ENGLAND
关键词
LITHIUM; HEMATOPOIESIS; MAIDS; RETROVIRAL INFECTION; IMMUNODEFICIENCY;
D O I
10.1016/0166-3542(94)00075-J
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lithium salts have been demonstrated to induce the production of hematopoietic cells following administration in vivo and to minimize the reduction of these cells following treatment with either radiation, chemotherapeutic or antiviral drugs. We have previously demonstrated that lithium, when administered in vivo to immunodeficient mice infected with LP-BM5 MuLV (MAIDS) significantly reduced the development of lymphadenopathy, splenomegaly, and the lymphoma associated with late-stage immunodeficiency disease in this model, and increased the survival of these animals compared to virus-infected controls not receiving lithium. We report here the results of in vivo studies in the MAIDS model that determined the effect of lithium on peripheral blood indices and the number of myeloid (CFU-GM), erythroid (BFU-E) and megakaryocyte (CFU-Meg) hematopoietic progenitors from bone marrow and spleen harvested from immunodeficient mice receiving lithium carbonate (1 mM) placed in their drinking water compared to virus-infected controls not receiving lithium. Time-points evaluated were at weeks 1, 5, 9, 13, 17, and 21 postviral infection. Virus-control mice not receiving lithium demonstrated all the signs that are characteristic of MAIDS, i.e., splenomegaly, lymphadenopathy, hypergammaglobulinemia, reduced hematopoiesis, and death. Infected mice receiving lithium demonstrated diminished presence of splenomegaly, lymphadenopathy, hypergammaglobulinemia, no suppression of hematopoiesis nor mortality. Enhanced hematopoiesis was demonstrated by neutrophilia, lymphocytosis, thrombocytosis, and erythrocytosis that was evident by increased myeloid, erythroid, and megakaryocyte progenitor cells cultured from bone marrow and spleen. These studies further demonstrate that lithium influences the disease process in the MAIDS model and restricts the development of hematopoietic suppression that develops in this retroviral animal model of immunodeficiency.
引用
收藏
页码:189 / 202
页数:14
相关论文
共 30 条
[1]   A POSSIBLE ANTIVIRAL ACTION OF LITHIUM-CARBONATE IN HERPES-SIMPLEX VIRUS-INFECTIONS [J].
AMSTERDAM, JD ;
MAISLIN, G ;
RYBAKOWSKI, J .
BIOLOGICAL PSYCHIATRY, 1990, 27 (04) :447-453
[2]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[3]  
Barrett A J, 1980, Adv Exp Med Biol, V127, P305
[4]  
BARRIOS NJ, 1992, LITHIUM, V2, P72
[5]   EFFECT OF LITHIUM IN MURINE IMMUNODEFICIENCY VIRUS-INFECTED ANIMALS [J].
GALLICCHIO, VS ;
CIBULL, ML ;
HUGHES, NK ;
TSE, KF .
PATHOBIOLOGY, 1993, 61 (3-4) :216-221
[6]   EFFECTIVE MODULATION OF THE HEMATOPOIETIC TOXICITY ASSOCIATED WITH ZIDOVUDINE EXPOSURE TO MURINE AND HUMAN HEMATOPOIETIC PROGENITOR STEM-CELLS INVITRO WITH LITHIUM-CHLORIDE [J].
GALLICCHIO, VS ;
HUGHES, NK .
JOURNAL OF INTERNAL MEDICINE, 1992, 231 (03) :219-226
[7]  
GALLICCHIO VS, 1980, BLOOD, V56, P1150
[8]   MODULATION OF THE HEMATOPOIETIC TOXICITY ASSOCIATED WITH ZIDOVUDINE INVIVO WITH LITHIUM-CARBONATE [J].
GALLICCHIO, VS ;
HUGHES, NK ;
TSE, KF .
JOURNAL OF INTERNAL MEDICINE, 1993, 233 (03) :259-268
[9]  
GALLICCHIO VS, 1994, LITHIUM, V5, P223
[10]  
GALLICCHIO VS, 1991, LITHIUM THERAPY MONO, P1